metformin vs glp 1 for pcos use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges - Saadati - 2025 - Diabetes, Obesity and Metabolism Semaglutide and metformin improve menstrual

According to their findings, 53.6% discontinued GLP-1 treatment by the end of year one, with higher rates of discontinuation (64.8%) seen among those using the drugs solely for weight loss, when compared with the 46.5% of those who quit after using the medications as a diabetes treatment

The widespread use of these drugs for weight loss has sparked debates as to the medicalisation of obesity and the ethics of using pharmaceuticals for body modification (Arillotta et al., 2023)

Increasing Rates of Obesity and Related Metabolic Disorders Various countries are reporting the growth for the obesity treatment market

To fine-tune these treatments, specific tests like fasting glucose (levels of 100 mg/dL suggest impaired fasting glucose), oral glucose tolerance tests, and HOMA-IR measurements are used